Erratum: Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment (Cancer Cell (2016) 30(6) (953–967) (S1535610816305050) (10.1016/j.ccell.2016.10.018));Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment

Cancer Cell

Volumn 30, Issue 6, 2016, Pages 953-967

  Park, Jin Sung ^a,b   Kim, Il Kug ^a   Han, Sangyeul ^b,c   Park, Intae ^a,b   Kim, Chan ^a   Bae, Jeomil ^b   Oh, Seung Ja ^c   Lee, Seungjoo ^d   Kim, Jeong Hoon ^d   Woo, Dong Cheol ^d   He, Yulong ^e   Augustin, Hellmut G ^f   Kim, Injune ^a   Lee, Doheon ^a,g   Koh, Gou Young ^a,b  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Institute for Basic Science   (South Korea)

^c Samsung Advanced Institute of Technology (SAIT)   (South Korea)

^d Asan Medical Center   (South Korea)

^e SOOCHOW UNIVERSITY   (China)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g Bio Synergy Research Center   (South Korea)

Author keywords

angiopoietin 2; enhanced drug delivery; M2 like TAM; Tie2 activation; tumor microenvironment; tumor vasculature; tumor vessel normalization

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; BLOCKING ANTIBODY; CISPLATIN; CLAUDIN 5; COLLAGEN TYPE 4; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TEMOZOLOMIDE; VASCULAR ENDOTHELIAL CADHERIN; ANG2 PROTEIN, MOUSE; ANTIBODY; ANTINEOPLASTIC AGENT; DACARBAZINE; PANCREATIC RIBONUCLEASE; PROTEIN BINDING; TEK PROTEIN, MOUSE;

ACIDOSIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN EDEMA; CANCER GROWTH; CANCER INHIBITION; CELL INFILTRATION; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; LACTIC ACIDOSIS; LEWIS CARCINOMA; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN INTERACTION; THERAPY EFFECT; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CANCER TRANSPLANTATION; CARCINOMA, LEWIS LUNG; DRUG EFFECTS; DRUG POTENTIATION; GLIOMA; METABOLISM; TREATMENT OUTCOME; VASCULARIZATION;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, LEWIS LUNG; DACARBAZINE; DRUG SYNERGISM; FEMALE; GLIOMA; HUMANS; MICE; NEOPLASM TRANSPLANTATION; PROTEIN BINDING; RECEPTOR, TIE-2; RIBONUCLEASE, PANCREATIC; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 85003894401     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.12.009     Document Type: Erratum

References (48)

1. Augustin, H.G., Koh, G.Y., Thurston, G., Alitalo, K., Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat. Rev. Mol. Cell Biol. 10 (2009), 165–177.
2. Bergers, G., Hanahan, D., Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8 (2008), 592–603.
3. Boroughs, L.K., DeBerardinis, R.J., Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 17 (2015), 351–359.
4. Brown, J.L., Cao, Z.A., Pinzon-Ortiz, M., Kendrew, J., Reimer, C., Wen, S., Zhou, J.Q., Tabrizi, M., Emery, S., McDermott, B., et al. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol. Cancer Ther. 9 (2010), 145–156.
5. Cao, Y., Arbiser, J., D'Amato, R.J., D'Amore, P.A., Ingber, D.E., Kerbel, R., Klagsbrun, M., Lim, S., Moses, M.A., Zetter, B., et al. Forty-year journey of angiogenesis translational research. Sci. Transl. Med., 3, 2011, 114rv113.
6. Carmeliet, P., Jain, R.K., Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10 (2011), 417–427.
7. Casanovas, O., Hicklin, D.J., Bergers, G., Hanahan, D., Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8 (2005), 299–309.
8. Chung, A.S., Ferrara, N., Developmental and pathological angiogenesis. Annu. Rev. Cell Dev. Biol. 27 (2011), 563–584.
9. Colegio, O.R., Chu, N.Q., Szabo, A.L., Chu, T., Rhebergen, A.M., Jairam, V., Cyrus, N., Brokowski, C.E., Eisenbarth, S.C., Phillips, G.M., et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513 (2014), 559–563.
10. Daly, C., Wong, V., Burova, E., Wei, Y., Zabski, S., Griffiths, J., Lai, K.M., Lin, H.C., Ioffe, E., Yancopoulos, G.D., Rudge, J.S., Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev. 18 (2004), 1060–1071.
11. Daly, C., Eichten, A., Castanaro, C., Pasnikowski, E., Adler, A., Lalani, A.S., Papadopoulos, N., Kyle, A.H., Minchinton, A.I., Yancopoulos, G.D., Thurston, G., Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 73 (2013), 108–118.
12. De Palma, M., Naldini, L., Angiopoietin-2 TIEs up macrophages in tumor angiogenesis. Clin. Cancer Res. 17 (2011), 5226–5232.
13. Doherty, J.R., Cleveland, J.L., Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest. 123 (2013), 3685–3692.
14. Ebos, J.M., Kerbel, R.S., Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8 (2011), 210–221.
15. Facciabene, A., Motz, G.T., Coukos, G., T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 72 (2012), 2162–2171.
16. Ferrara, N., Kerbel, R.S., Angiogenesis as a therapeutic target. Nature 438 (2005), 967–974.
17. Gatenby, R.A., Gillies, R.J., Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer 4 (2004), 891–899.
18. Gerstner, E.R., Duda, D.G., di Tomaso, E., Ryg, P.A., Loeffler, J.S., Sorensen, A.G., Ivy, P., Jain, R.K., Batchelor, T.T., VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat. Rev. Clin. Oncol. 6 (2009), 229–236.
19. Goel, S., Gupta, N., Walcott, B.P., Snuderl, M., Kesler, C.T., Kirkpatrick, N.D., Heishi, T., Huang, Y., Martin, J.D., Ager, E., et al. Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. J. Natl. Cancer Inst. 105 (2013), 1188–1201.
20. Han, S., Lee, S.J., Kim, K.E., Lee, H.S., Oh, N., Park, I., Ko, E., Oh, S.J., Lee, Y.S., Kim, D., et al. Amelioration of sepsis by TIE2 activation-induced vascular protection. Sci. Transl. Med., 8, 2016, 335ra55.
21. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
22. Hayashi, M., Majumdar, A., Li, X., Adler, J., Sun, Z., Vertuani, S., Hellberg, C., Mellberg, S., Koch, S., Dimberg, A., et al. VE-PTP regulates VEGFR2 activity in stalk cells to establish endothelial cell polarity and lumen formation. Nat. Commun., 4, 2013, 1672.
23. Hockel, M., Vaupel, P., Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93 (2001), 266–276.
24. Holopainen, T., Saharinen, P., D'Amico, G., Lampinen, A., Eklund, L., Sormunen, R., Anisimov, A., Zarkada, G., Lohela, M., Helotera, H., et al. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J. Natl. Cancer Inst. 104 (2012), 461–475.
25. Horska, A., Barker, P.B., Imaging of brain tumors: MR spectroscopy and metabolic imaging. Neuroimaging Clin. N. Am. 20 (2010), 293–310.
26. Hsu, P.P., Sabatini, D.M., Cancer cell metabolism: Warburg and beyond. Cell 134 (2008), 703–707.
27. Huang, H., Bhat, A., Woodnutt, G., Lappe, R., Targeting the ANGPT-TIE2 pathway in malignancy. Nat. Rev. Cancer 10 (2010), 575–585.
28. Hwang, J.A., Lee, E.H., Kim, H.W., Park, J.B., Jeon, B.H., Cho, C.H., COMP-Ang1 potentiates the antitumor activity of 5-fluorouracil by improving tissue perfusion in murine Lewis lung carcinoma. Mol. Cancer Res. 7 (2009), 1920–1927.
29. Jain, R.K., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005), 58–62.
30. Jain, R.K., Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26 (2014), 605–622.
31. Kienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., Herting, F., Yu, S., The, H.H., Martarello, L., et al. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin. Cancer Res. 19 (2013), 6730–6740.
32. Kim, C., Yang, H., Fukushima, Y., Saw, P.E., Lee, J., Park, J.S., Park, I., Jung, J., Kataoka, H., Lee, D., et al. Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption. Cancer Cell 25 (2014), 102–117.
33. Koh, G.Y., Orchestral actions of angiopoietin-1 in vascular regeneration. Trends Mol. Med. 19 (2013), 31–39.
34. Koh, Y.J., Kim, H.-Z., Hwang, S.-I., Lee, J.E., Oh, N., Jung, K., Kim, M., Kim, K.E., Kim, H., Lim, N.-K., et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 18 (2010), 171–184.
35. Lee, J., Kim, K.E., Choi, D.K., Jang, J.Y., Jung, J.J., Kiyonari, H., Shioi, G., Chang, W., Suda, T., Mochizuki, N., et al. Angiopoietin-1 guides directional angiogenesis through integrin alphavbeta5 signaling for recovery of ischemic retinopathy. Sci. Transl. Med., 5, 2013, 203ra127.
36. Maes, H., Kuchnio, A., Peric, A., Moens, S., Nys, K., De Bock, K., Quaegebeur, A., Schoors, S., Georgiadou, M., Wouters, J., et al. Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell 26 (2014), 190–206.
37. Mazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., Politi, L.S., Gentner, B., Brown, J.L., Naldini, L., De Palma, M., Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19 (2011), 512–526.
38. Nagy, J.A., Chang, S.H., Shih, S.C., Dvorak, A.M., Dvorak, H.F., Heterogeneity of the tumor vasculature. Semin. Thromb. Hemost. 36 (2010), 321–331.
39. Nasarre, P., Thomas, M., Kruse, K., Helfrich, I., Wolter, V., Deppermann, C., Schadendorf, D., Thurston, G., Fiedler, U., Augustin, H.G., Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res. 69 (2009), 1324–1333.
40. Oleinika, K., Nibbs, R.J., Graham, G.J., Fraser, A.R., Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin. Exp. Immunol. 171 (2013), 36–45.
41. Oliner, J., Min, H., Leal, J., Yu, D., Rao, S., You, E., Tang, X., Kim, H., Meyer, S., Han, S.J., et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6 (2004), 507–516.
42. Peterson, T.E., Kirkpatrick, N.D., Huang, Y., Farrar, C.T., Marijt, K.A., Kloepper, J., Datta, M., Amoozgar, Z., Seano, G., Jung, K., et al. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc. Natl. Acad. Sci. USA 113 (2016), 4470–4475.
43. Rivera, L.B., Bergers, G., Tumor angiogenesis, from foe to friend. Science 349 (2015), 694–695.
44. Scholz, A., Harter, P.N., Cremer, S., Yalcin, B.H., Gurnik, S., Yamaji, M., Di Tacchio, M., Sommer, K., Baumgarten, P., Bahr, O., et al. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol. Med. 8 (2015), 39–57.
45. Sheridan, C., Amgen's angiopoietin blocker fails in ovarian cancer. Nat. Biotechnol. 33 (2015), 5–6.
46. Srivastava, K., Hu, J., Korn, C., Savant, S., Teichert, M., Kapel, S.S., Jugold, M., Besemfelder, E., Thomas, M., Pasparakis, M., Augustin, H.G., Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. Cancer Cell 26 (2014), 880–895.
47. Van Slyke, P., Alami, J., Martin, D., Kuliszewski, M., Leong-Poi, H., Sefton, M.V., Dumont, D., Acceleration of diabetic wound healing by an angiopoietin peptide mimetic. Tissue Eng. Part A 15 (2009), 1269–1280.
48. Winkler, F., Kozin, S.V., Tong, R.T., Chae, S.S., Booth, M.F., Garkavtsev, I., Xu, L., Hicklin, D.J., Fukumura, D., di Tomaso, E., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6 (2004), 553–563.